Clinical Trials Logo

Parkinsons's Disease clinical trials

View clinical trials related to Parkinsons's Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01442610 Completed - Sleep Disturbances Clinical Trials

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease

RaSPar
Start date: October 2011
Phase: Phase 4
Study type: Interventional

As the MAO-B inhibitor rasagiline is able to improve motor skills it might have positive effects on sleep disruption by reducing nocturnal akinesia. As it was reported to cause only minor sleep disruption in PD Patients, it might be able to improve sleep architecture. The investigators thus study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and PDSS-2. Secondary measures are other sleep variables measured by PSG, sleep quality and daytime sleepiness assessed by standardized scales as well as cognitive function, depression and QoL index.

NCT ID: NCT01039090 Completed - Clinical trials for Parkinsons's Disease

Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease

APO-TEP
Start date: February 2009
Phase: Phase 3
Study type: Interventional

In Parkinson's disease, treatment mainly aims to improve motor functions. However, other dysfunctions are often observed in Parkinson's patients, and may have important consequences on the quality of life of patients. Cognitive and neuropsychological troubles may be observed, as memory impairment or anxiety for example. As this kind of troubles is worrying for the patient himself (herself) and his/her family, treatment needs to take into account those troubles in addition to motor difficulties. In our centre, we have already used continuous Apomorphine infusions among Parkinson's patients and it seems to have good results. The present study aims to objectively assess the efficacy of continuous Apomorphine infusions on cognitive and neuropsychological functions in Parkinson's disease using clinical and positron emission tomography (PET)-scan measures.